News & Events
March 25, 2021
C-Path Launches Acute Kidney Injury Project with Support from FDA
TUCSON, March 25, 2021 — Acute kidney injury (AKI) is a global, and potentially fatal, public health concern impacting nearly 13 million people per year. Defined clinically as an acute decrease in kidney function, AKI is associated with significant morbidity, mortality, and costs, with annual estimated health care expenditures ranging from $6.6 to $10 billion in the United States. AKI can be caused by dehydration, certain infections, and low blood flow to the kidneys, but it can also be caused by medications. This is known as drug-induced kidney injury (DIKI).
March 19, 2021
C-Path Names COO Kristen Swingle Interim President
TUCSON, Ariz., March 19, 2021 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer Kristen Swingle, M.S., has been appointed Interim President, effective immediately. Kristen succeeds Joseph Scheeren, Pharm.D., C-Path’s President and Chief Executive Officer since April 2019. Scheeren cited personal reasons for stepping down after stewarding C-Path through an important time of transformation, which has seen the organization add multiple new programs and more than doubled its staff.
March 10, 2021
C-Path Program and Consortia Leaders Selected to Serve in Sr. Vice President and Vice President Roles
TUCSON, Ariz., March 10, 2021 — Critical Path Institute (C-Path) today announced it has promoted Inish O’Doherty, Ph.D., to Vice President of the organization’s newly formed Immunology and Hematology Program and Sudhir Sivakumaran, Ph.D., to Vice President for its Neuroscience Program, effective immediately. Both Drs. O’Doherty and Sivakumaran currently serve as Executive Directors of multiple C-Path consortia. Additionally, current Program Officer Stephen Joel Coons, Ph.D., will now serve as Senior Vice President of the Clinical Outcome Assessment (COA) Program and John-Michael Sauer, Ph.D., as Senior Vice President of Translational and Safety Sciences Program.
December 3, 2020
C-Path, Ltd. Announces New Contract with Innovative Medicines InitiativeDUBLIN, Ireland, December 3, 2020 — Critical Path Institute, Ltd. (C-Path, Ltd.) announced today a new contract with the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU). The new project will leverage C-Path’s global expertise in developing novel product development tools. “The mission of IMI, to improve health by speeding up the development of,......
November 5, 2020
Pediatric IBD Foundation, ImproveCareNow, C-Path to Establish the Children’s Registry for the Advancement of Therapeutics
TUCSON, Ariz., November 5, 2020 — The Pediatric IBD Foundation, ImproveCareNow, and the Critical Path Institute (C-Path) are proud to announce a collaboration establishing the Children’s Registry for the Advancement of Therapeutics (CREATE™). CREATE™ is a drug-agnostic safety registry designed to support the completion of global post-marketing safety requirements, as well as collect safety information on all therapies used in pediatric IBD patients.